Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company's Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines' Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis ("ALS") and other neuromuscular disorders. This development is significant as it provides a robust intellectual property foundation for advancing gene therapy approaches that could address debilitating conditions with limited treatment options. By securing patent protection in Australia, Greenland Mines gains exclusivity in a key market, which could facilitate future clinical trials and commercialization efforts.
Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho's KLTO‑202 primary indication for ALS. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The issuance of this patent underscores the potential of the Klotho gene therapy platform, which aims to treat neuromuscular diseases by increasing expression of the Klotho protein, known for its neuroprotective and anti-aging properties. ALS, a progressive neurodegenerative disease affecting motor neurons, currently has no cure, making innovative therapies like KLTO-202 particularly important. The patent's broad claims covering delivery systems and cell types could provide a competitive advantage as the company moves toward clinical development.
For more information on the original announcement, visit the full press release at https://nnw.fm/PVbbH. Additional updates on GRML are available in the company's newsroom at https://nnw.fm/GRML.
